Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Kallikrein 6 protease advances colon tumorigenesis via induction of the high mobility group A2 protein.

Chen H, Sells E, Pandey R, Abril ER, Hsu CH, Krouse RS, Nagle RB, Pampalakis G, Sotiropoulou G, Ignatenko NA.

Oncotarget. 2019 Oct 22;10(58):6062-6078. doi: 10.18632/oncotarget.27153. eCollection 2019 Oct 22.

2.

Does Mutated K-RAS Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention?

Rice PFS, Ehrichs KG, Jones MS, Chen H, Hsu CH, Abril ER, Nagle RB, Besselsen DG, Barton JK, Ignatenko NA.

Cancer Prev Res (Phila). 2018 Jan;11(1):16-26. doi: 10.1158/1940-6207.CAPR-17-0230. Epub 2017 Nov 8.

3.

Detection of Enzyme Activity and Inhibition during Studies in Solution, In Vitro and In Vivo with CatalyCEST MRI.

Sinharay S, Randtke EA, Howison CM, Ignatenko NA, Pagel MD.

Mol Imaging Biol. 2018 Apr;20(2):240-248. doi: 10.1007/s11307-017-1092-8.

4.

Specific microRNA-mRNA Regulatory Network of Colon Cancer Invasion Mediated by Tissue Kallikrein-Related Peptidase 6.

Sells E, Pandey R, Chen H, Skovan BA, Cui H, Ignatenko NA.

Neoplasia. 2017 May;19(5):396-411. doi: 10.1016/j.neo.2017.02.003. Epub 2017 Apr 18.

5.

Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways.

Padavano J, Henkhaus RS, Chen H, Skovan BA, Cui H, Ignatenko NA.

Cancer Growth Metastasis. 2015 Oct 19;8(Suppl 1):95-113. doi: 10.4137/CGM.S29407. eCollection 2015.

6.

Time-serial Assessment of Drug Combination Interventions in a Mouse Model of Colorectal Carcinogenesis Using Optical Coherence Tomography.

LeGendre-McGhee S, Rice PS, Wall RA, Sprute KJ, Bommireddy R, Luttman AM, Nagle RB, Abril ER, Farrell K, Hsu CH, Roe DJ, Gerner EW, Ignatenko NA, Barton JK.

Cancer Growth Metastasis. 2015 Sep 7;8(Suppl 1):63-80. doi: 10.4137/CGM.S21216. eCollection 2015.

7.

Get the fat out!

Ignatenko NA, Gerner EW.

Cancer Prev Res (Phila). 2013 Mar;6(3):161-4. doi: 10.1158/1940-6207.CAPR-13-0025.

8.

Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis.

Basu Roy UK, Henkhaus RS, Loupakis F, Cremolini C, Gerner EW, Ignatenko NA.

Int J Cancer. 2013 Jul;133(1):43-57. doi: 10.1002/ijc.28001. Epub 2013 Feb 12. Erratum in: Int J Cancer. 2015 Oct 15;137(8):E18.

9.

Polyamines in cancer.

Paz EA, Garcia-Huidobro J, Ignatenko NA.

Adv Clin Chem. 2011;54:45-70. Review.

PMID:
21874756
10.

Defining the role of polyamines in colon carcinogenesis using mouse models.

Ignatenko NA, Gerner EW, Besselsen DG.

J Carcinog. 2011;10:10. doi: 10.4103/1477-3163.79673. Epub 2011 Apr 16.

11.

Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047.

Ignatenko NA, Yerushalmi HF, Pandey R, Kachel KL, Stringer DE, Marton LJ, Gerner EW.

Cancer Genomics Proteomics. 2009 May-Jun;6(3):161-75.

12.

Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.

Ignatenko NA, Besselsen DG, Stringer DE, Blohm-Mangone KA, Cui H, Gerner EW.

Nutr Cancer. 2008;60 Suppl 1:30-5. doi: 10.1080/01635580802401317.

PMID:
19003578
13.

Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells.

Henkhaus RS, Gerner EW, Ignatenko NA.

Biol Chem. 2008 Jun;389(6):757-64. doi: 10.1515/BC.2008.087.

14.

Wild-type APC regulates caveolin-1 expression in human colon adenocarcinoma cell lines via FOXO1a and C-myc.

Roy UK, Henkhaus RS, Ignatenko NA, Mora J, Fultz KE, Gerner EW.

Mol Carcinog. 2008 Dec;47(12):947-55. doi: 10.1002/mc.20451.

15.

HuRrying colon cancer progression.

Ignatenko NA, Gerner EW.

Cancer Biol Ther. 2008 Mar;7(3):428-9. Epub 2007 Feb 2. No abstract available.

16.

Caveolin-1-mediated expression and secretion of kallikrein 6 in colon cancer cells.

Henkhaus RS, Roy UK, Cavallo-Medved D, Sloane BF, Gerner EW, Ignatenko NA.

Neoplasia. 2008 Feb;10(2):140-8.

17.

Serial endoscopy in azoxymethane treated mice using ultra-high resolution optical coherence tomography.

Hariri LP, Qiu Z, Tumlinson AR, Besselsen DG, Gerner EW, Ignatenko NA, Povazay B, Hermann B, Sattmann H, McNally J, Unterhuber A, Drexler W, Barton JK.

Cancer Biol Ther. 2007 Nov;6(11):1753-62. Epub 2007 Aug 12.

PMID:
17986850
18.

Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis.

Ignatenko NA, Besselsen DG, Roy UK, Stringer DE, Blohm-Mangone KA, Padilla-Torres JL, Guillen-R JM, Gerner EW.

Nutr Cancer. 2006;56(2):172-81.

19.

Deoxycholate-induced colitis is markedly attenuated in Nos2 knockout mice in association with modulation of gene expression profiles.

Bernstein H, Holubec H, Bernstein C, Ignatenko NA, Gerner E, Dvorak K, Besselsen D, Blohm-Mangone KA, Padilla-Torres J, Dvorakova B, Garewal H, Payne CM.

Dig Dis Sci. 2007 Mar;52(3):628-42.

PMID:
17253130
20.

Pharmacogenomics of the polyamine analog 3,8,13,18-tetraaza-10,11-[(E)-1,2-cyclopropyl]eicosane tetrahydrochloride, CGC-11093, in the colon adenocarcinoma cell line HCT1161.

Ignatenko NA, Yerushalmi HF, Watts GS, Futscher BW, Stringer DE, Marton LJ, Gerner EW.

Technol Cancer Res Treat. 2006 Dec;5(6):553-64.

PMID:
17121431
21.

Role of c-Myc in intestinal tumorigenesis of the ApcMin/+ mouse.

Ignatenko NA, Holubec H, Besselsen DG, Blohm-Mangone KA, Padilla-Torres JL, Nagle RB, de Alboránç IM, Guillen-R JM, Gerner EW.

Cancer Biol Ther. 2006 Dec;5(12):1658-64. Epub 2006 Dec 7.

PMID:
17106247
22.

Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival.

Zell JA, Ignatenko NA, Yerushalmi HF, Ziogas A, Besselsen DG, Gerner EW, Anton-Culver H.

Int J Cancer. 2007 Feb 1;120(3):459-68.

23.

Role of polyamines in arginine-dependent colon carcinogenesis in Apc(Min) (/+) mice.

Yerushalmi HF, Besselsen DG, Ignatenko NA, Blohm-Mangone KA, Padilla-Torres JL, Stringer DE, Guillen JM, Holubec H, Payne CM, Gerner EW.

Mol Carcinog. 2006 Oct;45(10):764-73.

PMID:
16705737
24.

A comprehensive strategy to combat colon cancer targeting the adenomatous polyposis coli tumor suppressor gene.

Gerner EW, Ignatenko NA, Lance P, Hurley LH.

Ann N Y Acad Sci. 2005 Nov;1059:97-105. Review.

PMID:
16382048
25.

The role of NO synthases in arginine-dependent small intestinal and colonic carcinogenesis.

Yerushalmi HF, Besselsen DG, Ignatenko NA, Blohm-Mangone KA, Padilla-Torres JL, Stringer DE, Cui H, Holubec H, Payne CM, Gerner EW.

Mol Carcinog. 2006 Feb;45(2):93-105.

PMID:
16329147
26.

The chemopreventive agent alpha-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells.

Ignatenko NA, Zhang H, Watts GS, Skovan BA, Stringer DE, Gerner EW.

Mol Carcinog. 2004 Apr;39(4):221-33.

PMID:
15057874
27.

Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells.

Ignatenko NA, Babbar N, Mehta D, Casero RA Jr, Gerner EW.

Mol Carcinog. 2004 Feb;39(2):91-102.

PMID:
14750214
28.

Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer.

Babbar N, Ignatenko NA, Casero RA Jr, Gerner EW.

J Biol Chem. 2003 Nov 28;278(48):47762-75. Epub 2003 Sep 23.

29.

Preclinical models for chemoprevention of colon cancer.

Gerner EW, Ignatenko NA, Besselsen DG.

Recent Results Cancer Res. 2003;163:58-71; discussion 264-6. Review.

PMID:
12903843
30.

Regulation of the HIV1 long terminal repeat by mutant heat shock factor.

Ignatenko NA, Gerner EW.

Exp Cell Res. 2003 Aug 1;288(1):1-8.

PMID:
12878154
31.

Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine.

Qu N, Ignatenko NA, Yamauchi P, Stringer DE, Levenson C, Shannon P, Perrin S, Gerner EW.

Biochem J. 2003 Oct 15;375(Pt 2):465-70.

32.

Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells.

Taylor MT, Lawson KR, Ignatenko NA, Marek SE, Stringer DE, Skovan BA, Gerner EW.

Cancer Res. 2000 Dec 1;60(23):6607-10.

33.

Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine.

Lawson KR, Ignatenko NA, Piazza GA, Cui H, Gerner EW.

Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1155-62.

34.

APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse.

Erdman SH, Ignatenko NA, Powell MB, Blohm-Mangone KA, Holubec H, Guillén-Rodriguez JM, Gerner EW.

Carcinogenesis. 1999 Sep;20(9):1709-13.

PMID:
10469614
35.

Expression of the human spermidine/spermine N1-acetyltransferase in spermidine acetylation-deficient Escherichia coli.

Ignatenko NA, Fish JL, Shassetz LR, Woolridge DP, Gerner EW.

Biochem J. 1996 Oct 15;319 ( Pt 2):435-40.

36.
37.

Ornithine decarboxylase activity and polyamine content in adenocarcinomas of human stomach and large intestine.

Berdinskikh NK, Ignatenko NA, Zaletok SP, Ganina KP, Chorniy VA.

Int J Cancer. 1991 Feb 20;47(4):496-8.

PMID:
1995479
38.
39.

[Increase in ornithine decarboxylase activity and polyamine levels of the rat liver during an early period of hepatocarcinogenesis].

Berdinskikh NK, Zaletok SP, Ignatenko NA, Draga NV.

Ukr Biokhim Zh (1978). 1988 Jan-Feb;60(1):94-7. Russian.

PMID:
3363681
40.

[Ornithine decarboxylase activity and polyamine content in human adenocarcinomas of the stomach and large intestine].

Berdinskikh NK, Zaletok SP, Bobro LI, Ignatenko NA.

Eksp Onkol. 1988;10(6):39-41. Russian.

PMID:
3243193
41.

[Sphygmographic equipment 064].

Naruzhnyĭ BV, Ignatenko NA.

Med Prom SSSR. 1965 Sep;19(9):51-4. Russian. No abstract available.

PMID:
5868312

Supplemental Content

Loading ...
Support Center